1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2020, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 8, 46, 42, 1, 29, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 7 and 8 molecules, respectively.
Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionMalignant Mesothelioma - Overview
Malignant Mesothelioma - Therapeutics Development
Malignant Mesothelioma - Therapeutics Assessment
Malignant Mesothelioma - Companies Involved in Therapeutics Development
Malignant Mesothelioma - Drug Profiles
Malignant Mesothelioma - Dormant Projects
Malignant Mesothelioma - Discontinued Products
Malignant Mesothelioma - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Malignant Mesothelioma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Malignant Mesothelioma - Pipeline by AbbVie Inc, H2 2020
- Malignant Mesothelioma - Pipeline by ADCendo ApS, H2 2020
- Malignant Mesothelioma - Pipeline by Agios Pharmaceuticals Inc, H2 2020
- Malignant Mesothelioma - Pipeline by Akeso Inc, H2 2020
- Malignant Mesothelioma - Pipeline by Aldeyra Therapeutics Inc, H2 2020
- Malignant Mesothelioma - Pipeline by Almac Discovery Ltd, H2 2020
- Malignant Mesothelioma - Pipeline by Amphera BV, H2 2020
- Malignant Mesothelioma - Pipeline by AnGes Inc, H2 2020
- Malignant Mesothelioma - Pipeline by Apollomics Inc, H2 2020
- Malignant Mesothelioma - Pipeline by Applied Research using OMIC Sciences SL, H2 2020
- Malignant Mesothelioma - Pipeline by Arch Oncology Inc, H2 2020
- Malignant Mesothelioma - Pipeline by Argenx SE, H2 2020
- Malignant Mesothelioma - Dormant Projects, H2 2020
- Malignant Mesothelioma - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Malignant Mesothelioma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- ADCendo ApS
- Agios Pharmaceuticals Inc
- Akeso Inc
- Aldeyra Therapeutics Inc
- Almac Discovery Ltd
- Amphera BV
- AnGes Inc
- Apollomics Inc
- Applied Research using OMIC Sciences SL
- Arch Oncology Inc
- Argenx SE
- Ascentage Pharma Group International
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Aurigene Discovery Technologies Ltd
- Bao Kang Biomedical Healthcare Inc
- Bayer AG
- BerGenBio ASA
- Biocad
- Biogen Inc
- Bionomics Ltd
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- CanBas Co Ltd
- Canget BioTekpharma LLC
- Checkpoint Therapeutics Inc
- Chiome Bioscience Inc
- Clovis Oncology Inc
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Deciphera Pharmaceuticals Inc
- Delta-Fly Pharma Inc
- Eisai Co Ltd
- Eli Lilly and Co
- EnGeneIC Ltd
- Epigene Therapeutics Inc
- Epizyme Inc
- Eureka Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- FKD Therapies Oy
- Flag Therapeutics Inc
- Genelux Corp
- GlaxoSmithKline Plc
- H2Biologics Inc
- Harpoon Therapeutics Inc
- Hebei Senlang Biotechnology Inc Ltd
- Horizon Therapeutics Plc
- Hutchison MediPharma Ltd
- IDAC Theranostics Inc
- Ikena Oncology Inc
- Incyte Corp
- Infinity Pharmaceuticals Inc
- Inhibrx Inc
- Inventiva
- Invion Ltd
- iOnctura SA
- Juno Therapeutics Inc
- Karyopharm Therapeutics Inc
- Kiromic BioPharma Inc
- Kyowa Kirin Co Ltd
- L.E.A.F. Pharmaceuticals LLC
- Laboratoires Pierre Fabre SA
- Lipac Oncology LLC
- LipoSeuticals Inc
- MacroGenics Inc
- Marino Biotechnology Co Ltd
- MaxCyte Inc
- MELEMA Pharma GmbH
- Merck & Co Inc
- Merck KGaA
- Millennium Pharmaceuticals Inc
- Minneamrita Therapeutics LLC
- Molecular Partners AG
- MolMed SpA
- Momotaro-Gene Inc
- MTG Biotherapeutics Inc
- NeoTX Therapeutics Ltd
- Novartis AG
- Oasmia Pharmaceutical AB
- Oncology Venture A/S
- Oncovir Inc
- Ono Pharmaceutical Co Ltd
- OSE Immunotherapeutics
- Pharma Mar SA
- PlumeStars Srl
- Polaris Pharmaceuticals Inc
- Quadriga BioSciences Inc
- Seattle Genetics Inc
- SELLAS Life Sciences Group Inc
- Shanghai GeneChem Co Ltd
- Shanghai Keqi Pharmaceutical Technology Co Ltd
- Shionogi & Co Ltd
- Sotio AS
- Sumitomo Dainippon Pharma Oncology, Inc
- Targovax ASA
- TCR2 Therapeutics Inc
- TRACON Pharmaceuticals Inc
- TREAT U SA
- Ube Industries Ltd
- Ultimovacs AS
- VasGene Therapeutics Inc
- Venus Remedies Ltd
- Verastem Inc
- VM Discovery Inc
- Xencor Inc
- Y's Therapeutics Co Ltd
- Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
